These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7699234)

  • 21. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.
    Manesis EK; Hadziyannis ES; Angelopoulou OP; Hadziyannis SJ
    Antivir Ther; 2007; 12(1):73-82. PubMed ID: 17503750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally.
    Zielińska W; Paszkiewicz J; Korczak A; Własiuk M; Zółtowska A; Szutowicz A; Cummins JM; Georgiades JA
    Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):241-51. PubMed ID: 8129568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Li ZZ; Wu SL; Liu RY; Chang M; Hu LP; Hua WH; Song SJ; Wan G; Xie Y
    Biomed Environ Sci; 2017 Mar; 30(3):177-184. PubMed ID: 28427487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
    Niederau C; Heintges T; Lange S; Goldmann G; Niederau CM; Mohr L; Häussinger D
    N Engl J Med; 1996 May; 334(22):1422-7. PubMed ID: 8618580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hepatitis B virus-associated nephropathy in black children.
    Bhimma R; Coovadia HM; Kramvis A; Adhikari M; Kew MC
    Pediatr Nephrol; 2002 Jun; 17(6):393-9. PubMed ID: 12107801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers.
    Chu CM; Sheen IS; Lin SM; Liaw YF
    Clin Infect Dis; 1993 May; 16(5):709-13. PubMed ID: 8507764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up.
    Perez V; Findor J; Tanno H; Sordá J
    Gut; 1993; 34(2 Suppl):S91-4. PubMed ID: 8314497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B].
    Aşik Akman S; Cokçeken Okçu S; Anil OH; Köse S; Bakiler AR
    Mikrobiyol Bul; 2006; 40(1-2):47-53. PubMed ID: 16775956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children.
    Lai CL; Lin HJ; Lau JN; Flok AS; Wu PC; Chung HT; Wong LK; Leung MP; Yeung CY
    Q J Med; 1991 Feb; 78(286):155-63. PubMed ID: 2031078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant leukocyte interferon treatment of chronic hepatitis B.
    Dusheiko G; Dibisceglie A; Bowyer S; Sachs E; Ritchie M; Schoub B; Kew M
    Hepatology; 1985; 5(4):556-60. PubMed ID: 4018728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic infection due to hepatitis B virus in patients less than 16 years of age: therapeutic approach by means of interferon alfa-2b].
    Vetencourt R; Oropeza F; de Armas J; Cordero I; de Silva M; Machado I; Vetencourt M; Mendoza J
    G E N; 1990; 44(4):353-60. PubMed ID: 2152277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
    Di Bisceglie AM; Fong TL; Fried MW; Swain MG; Baker B; Korenman J; Bergasa NV; Waggoner JG; Park Y; Hoofnagle JH
    Am J Gastroenterol; 1993 Nov; 88(11):1887-92. PubMed ID: 8237937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients.
    Yang N; Feng J; Zhou T; Li Z; Chen Z; Ming K; Liang G; Lei XX; Xu BL
    J Med Virol; 2018 Jul; 90(7):1240-1245. PubMed ID: 29603789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
    J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B.
    Hayashi J; Kajiyama W; Noguchi A; Nakashima K; Hirata M; Hayashi S; Kashiwagi S
    Gastroenterol Jpn; 1991 Dec; 26(6):742-6. PubMed ID: 1765247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.